Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NODE-202 pediatric etripamil study in paroxysmal supraventricular tachycardia
2022-500319-38-00Phase 2Authorised
- Sponsor
- Milestone Pharmaceuticals
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of etripamil in paroxysmal supraventricular tachycardia (PSVT), sponsored by Milestone Pharmaceuticals. Primary endpoint: Conversion to sinus rhythm within 15 minutes. Planned start Aug 2023; status: authorised.
02
Drugs
etripamil
03
Conditions
paroxysmal supraventricular tachycardia (PSVT)
Beyond the preview
Go deeper on 2022-500319-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500319-38-00.